Skip to main content
Fig. 3 | BMC Immunology

Fig. 3

From: Autoantibodies against BAFF, APRIL or IL21 - an alternative pathogenesis for antibody-deficiencies?

Fig. 3

Functional Analysis. In Panel (a) and (b) the results of the B cell survival assay are displayed. In Panel (a) viable (b) cells (CD19+,DAPI-) are shown after 9 days-incubation with patient sera, which were selected for their high anti-BAFF-ELISA results. Pat.1185 had received Rituximab-treatment prior to serum withdrawal; hence the results were not conclusive. Panel (b) shows the amount of viable (b) cells after the addition of sera with putative anti-APRIL antibodies. The results show no significant difference. In Panel (c) the results of the STAT3 phosphorylation assay are shown. PBMCs were incubated with IL-21 as well as selected healthy donor and patient sera. pSTAT3 was measured by FACS analysis. No marked disparity was observed between patients and healthy donors

Back to article page